Logo of plosntdPLoS Neglected Tropical DiseasesView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS Negl Trop Dis. Jan 2012; 6(1): e1453.
Published online Jan 3, 2012. doi:  10.1371/journal.pntd.0001453
PMCID: PMC3250505

The Genetic and Molecular Basis of O-Antigenic Diversity in Burkholderia pseudomallei Lipopolysaccharide

Craig R. Roy, Editor

Abstract

Lipopolysaccharide (LPS) is one of the most important virulence and antigenic components of Burkholderia pseudomallei, the causative agent of melioidosis. LPS diversity in B. pseudomallei has been described as typical, atypical or rough, based upon banding patterns on SDS-PAGE. Here, we studied the genetic and molecular basis of these phenotypic differences. Bioinformatics was used to determine the diversity of genes known or predicted to be involved in biosynthesis of the O-antigenic moiety of LPS in B. pseudomallei and its near-relative species. Multiplex-PCR assays were developed to target diversity of the O-antigen biosynthesis gene patterns or LPS genotypes in B. pseudomallei populations. We found that the typical LPS genotype (LPS genotype A) was highly prevalent in strains from Thailand and other countries in Southeast Asia, whereas the atypical LPS genotype (LPS genotype B) was most often detected in Australian strains (~13.8%). In addition, we report a novel LPS ladder pattern, a derivative of the atypical LPS phenotype, associated with an uncommon O-antigen biosynthesis gene cluster that is found in only a small B. pseudomallei sub-population. This new LPS group was designated as genotype B2. We also report natural mutations in the O-antigen biosynthesis genes that potentially cause the rough LPS phenotype. We postulate that the diversity of LPS may correlate with differential immunopathogenicity and virulence among B. pseudomallei strains.

Author Summary

Burkholderia pseudomallei is an environmental Gram-negative bacterium and the cause of melioidosis, an often life-threatening disease affecting people in Southeast Asia and northern Australia. Melioidosis is usually contracted by bacterial inoculation, ingestion or inhalation. Effective vaccines for melioidosis are currently unavailable. This organism contains a large genome, which varies greatly among strains due to a high frequency of genetic recombination. We report here on diversity of lipopolysaccharides (LPS) in this species, a major component of the bacterial outer membrane and a known immunogenic virulence factor. We developed LPS genotyping techniques to study frequency of two major LPS types, known as typical and atypical LPS, in B. pseudomallei strains collected from two endemic regions: Southeast Asia and Northern Australia. LPS genotype variation differed among B. pseudomallei populations. During the investigation, we discovered a new LPS genotype in a sub-population group of B. pseudomallei in Australia. We postulate that such differences are likely to be associated with variable immunopathogenicity and clinical presentation in the human host.

Introduction

Lipopolysaccharide (LPS) is a major component of the outer membrane of Gram-negative bacteria, playing an important role in cell integrity and in signaling host innate immune response [1]. Structurally, LPS is composed of three major components: lipid A, the bacterial endotoxin that is embedded in the phospholipid bilayer of the outer membrane; core-oligosaccharide; and O-antigen. These three components are linked together as a part of the bacterial outer membrane. In a highly pathogenic bacterial species, such as Burkholderia pseudomallei, LPS has a major role in stimulating host innate immune response during infection [2]. B. pseudomallei LPS has been classified as a type II O-polysaccharide (O-PS) and is one of 4 different surface polysaccharides produced by this pathogen [3]. Previous studies have shown that B. pseudomallei LPS is required for serum resistance and virulence [4]. It has been well established in many bacterial diseases that overstimulation of the host cells by LPS can lead to the features of septic shock [5]. Likewise for B. pseudomallei, septicemia is a major cause of death. In Northeast Thailand especially in Ubon Ratchathani Province where melioidosis is highly endemic, the average incidence rate of melioidosis is 12.7 cases per 100,000 people per year with the average of 42.6% of mortality rate [6]. Cellular recognition of LPS by the innate immune system triggers the proinflammatory cytokines by host cells, which aids in the clearance of the pathogen. Previous studies have supported a potential role for B. pseudomallei LPS in protective immunity, with high concentrations of antibodies to LPS associated with survival in severe melioidosis [7], [8]. As a result, LPS has been used in vaccine development and provided protective immunity in a murine model of melioidosis [2]. In addition, it was demonstrated that LPS had an important role in bacterial virulence because the LPS mutant B. pseudomallei strain SRM117, which lacked the O-antigenic polysaccharide moiety was more susceptible to macrophage killing during the early phase of infection than its parental strain 1026b [9].

A previous study [10] identified LPS diversity based upon electrophoretic mobility with SDS-PAGE and detection using immunoblot analysis. This diversity included two serotypes (A and B) possessing different electrophoretic ladder profiles and a rough type that did not contain the ladder patterns; all were antigenically distinct [10]. Molecular structure of O-antigen serotype A or typical type has been described as the unbranched heteropolymers consisting of disaccharides repeats of -3)-β-D-glucopyranose-(1-3)-6-deoxy-α-L-talopyranose-(1- in which approx. 33% of the L-6dTalp residues bear 2-O-methyl and 4-O-acetyl substituents whereas the other L-6dTalp residues carry only 2-O-acetyl substituents [11]. We note that the structures are not known for any of the other B. pseudomallei O-antigens. B. thailandensis, a genetically related non-pathogenic species, has LPS that is cross-reactive to sera obtained from B. pseudomallei and B. mallei infections, and this has led to the development of a vaccine for melioidosis using LPS from B. thailandensis [12]. B. mallei, the causative agent of glanders, has O-antigen structure similar to those found in B. pseudomallei and B. thailandensis, except that it has different side-group modifications at the L-6dTalp residues which lack the acetylation at the O-4 position [13]. These structural differences are associated with the absence of oacA gene in B. mallei. oacA encodes for O-antigen acetylase A in B. thailandensis and its homolog in B. pseudomallei K96243 is identified as BPSL1936 [14].

B. pseudomallei genomes are very diverse due to horizontal gene transfer events [15], [16] and dynamic changes in repeated sequences [17]. This results in diverse phenotypic characteristics such as bacterial colony morphotypes [18], and importantly, may be implicated in the diverse clinical manifestations observed among melioidosis patients. The latter range from asymptomatic cases, to localized infections, to whole body sepsis, along with differential seroreactivities [19], all of which may be correlated with the great genomic diversity in this species [15], [17]. Nevertheless, the specific roles of genetic diversity in B. pseudomallei in differential clinical presentations of melioidosis requires further analysis, as clinical studies suggest host risk factors are the major determinant of disease severity [20]. Because LPS phenotypic diversity is important for serology and diagnostics, we investigated the genetic and molecular basis of differential LPS phenotypes in a large B. pseudomallei population. Bioinformatics, phenotypic characterization, as well as, population genetics approach were used in this study to better understand this important trait.

Methods

Comparative genomics of LPS biosynthesis genes

Artemis and Artemis Comparison Tool (ACT) software [21] was used to display and compare multiple B. pseudomallei genomes. Genomes and nucleotide sequences used in this study are listed in Table 1. Mutations in O-antigen biosynthesis genes were identified using basic homologous gene based alignments.

Table 1
LPS genotype identification and mutations in the four closely related Burkholderia species.

PCR Analysis

Multiplex-SYBR-Green PCR assays were designed to target 3 different LPS genotypes. Gene wbiE of B. pseudomallei K96243, gene BUC_3396 of B. pseudomallei 576, and gene BURP840_LPSb16 of B. pseudomallei MSHR840 were used as the PCR markers to investigate frequency of LPS genotypes A, B, and B2, respectively (Figures 1&2). PCR primers used in this study are as follows: wbiE_F, 5′-TCAAACCTATCCGCGTGTCGAAGT-3′; wbiE_R, 5′-TCGTCGTCAAGAAATCCCAGCCAT-3′; BUC3396_ F, 5′-AATCTTTTTCTGATTCCGTCC-3′; BUC3396_R, 5′ -ACCAGAAGACAAGGAGAAAGGCCA-3′; BURP840_LPSb16_F, 5′-AACCGGGTAGTTCGCGATTAC-3′; and BURP840_LPSb16_R, 5′-ATACGCCGGTGTAGAACAGTA-3′. The PCR assay was conducted in 10-µL reaction mixtures containing 1× SYBR-Green master mix (Applied Biosystems, USA), 0.3 µM of each PCR primer, and 0.1 to 1.0 ng of DNA template. Most tested DNA samples were made in collaborative laboratories in Thailand and Australia using various DNA extraction techniques. The reactions were performed on an ABI 7900HT Sequence Detection System (Applied Biosystems, USA) utilizing 40 cycles. Each cycle contained two steps: denaturation at 95°C for 15 s and annealing at 60°C for 30 s. The PCR products were further analyzed by melting them continuously from 60°C to 95°C to generate a dissociation curve. The melting temperatures of PCR amplicons for genes wbiE, BUC_3396, and BURP840_LPSb16 were constant at 87.0°C, 83°C, and 88.5°C, respectively. We used this assay to analyze DNA templates from 999 diverse B. pseudomallei strains isolated from clinical, animal, and environmental samples from Australia (n = 600), Thailand (n = 349), Malaysia (n = 27), Vietnam (n = 7), Papua New Guinea (n = 2), and unknown countries in Southeast Asia (n = 14), as well as 77 B. thailandensis strains, 2 B. thailandensis-like spp. strains, and 37 strains of unknown soil bacteria.

Figure 1
Diversity of three biosynthesis gene clusters for the O-antigen moiety of the LPS in B. pseudomallei.
Figure 2
Genotyping scheme and frequencies of three different LPS genotypes identified in B. pseudomallei populations.

DNA sequencing and analysis

Whole genome sequencing was performed using 454 sequencing technology (Roche, USA) by US Army Edgewood Chemical Biological Center (ECBC), MD, USA. Artemis –based analysis and BLAST were used to annotate the O-antigen biosynthesis genes of B. pseudomallei strains MSHR840, MSHR139, and MSHR1950. DNA sequencing for wbiI and oacA genes was performed using ABI 3130×l Genetic Analyzer (Applied Biosystems, USA).

LPS identification and characterization: Techniques for LPS extraction and SDS-PAGE analysis followed a previous study [10]. Immunoblot analysis was performed using sera from melioidosis patients with known infection with B. pseudomallei LPS genotype A or B strains as the primary antibodies. Horse radish peroxidase (HRP) – conjugated anti-human IgG was used as the secondary antibody in a standard immunoblot analysis. Monoclonal antibody 3D11, the B. mallei LPS-specific mAb (Research Diagnostics Inc., USA), was used as a primary antibody in the immunoblot analysis of the oacA mutant strains.

Serum susceptibility tests

Select B. pseudomallei strains were tested for growth, multiplication, and survival in the presence of 30% normal human serum (NHS) as previously described [4] with some modifications. Briefly, each B. pseudomallei strain was inoculated in a 2 mL of TSBDC media and incubated overnight at 37°C and 250 rpm in an orbital shaker. The overnight culture (100 µL) was used to inoculate 3 mL of TSBDC media and then incubated at the same conditions for 4 hr to reach mid exponential growth phase. Serum susceptibility tests were performed in 1.5 mL microfuge tubes containing 100 µL of bacterial culture, 300 µL of NHS (Lonza Inc., USA), and 600 µL PBS. The mixture was incubated at 37°C for 2 hr, and then the number of viable bacterial cells was determined using plate counting. B. pseudomallei 1026b and E. coli HB101 were used as positive and negative controls in this study, respectively.

GenBank Accessions

Nucleotide sequences and annotations of the O-antigen biosynthesis genes in B. pseudomallei strains MSHR840, MSHR139, and MSHR1950LPS were submitted to GenBank under accession nos. GU574442, HM852063, and HM852062, respectively.

Results

To better understand the diversity of genes responsible for the biosynthesis of O-antigen moiety of the LPS in B. pseudomallei, we first used a comparative analysis of all publicly available B. pseudomallei genomes to identify differences within LPS biosynthetic genes. Three different O-antigen biosynthesis gene categories, or genotypes, were identified. Secondly, we examined the genotype frequencies in B. pseudomallei populations using PCR assays targeting each of these genetic types. Thirdly, we correlated LPS genotypes with their differential phenotypes (serotypes). This led to our discovery of a natural mutation in an O-antigen biosynthesis gene in a clonal panel of B. pseudomallei strains isolated from a single human host. The adaptability of B. pseudomallei strains through LPS variation, even within a single human host, represents an important aspect of pathogen biology and a complication for melioidosis host response.

Diversity of O-antigen biosynthesis genes in B. pseudomallei and its near-relative species

We compared 27 B. pseudomallei, 10 B. mallei, 3 B. thailandensis, and 2 B. oklahomensis genomes (Table 1) to identify the LPS O-antigen biosynthesis genes. Assuming synteny and common genomic locations, along with known or predicted function, B. pseudomallei O-antigen biosynthesis genes were assigned to two major groups. Group A (LPS genotype A) was identical or very similar to the O-antigen biosynthesis operon observed in B. pseudomallei 1026b [4], whereas group B (LPS genotype B) was found in an atypical LPS strain 576 and also in the species type strain, NCTC13177. LPS genotype A was found in most B. pseudomallei and all B. mallei and B. thailandensis genomes examined. Surprisingly, the more distantly related B. oklahomensis strain EO147 also had LPS genotype A, which was different from the predicted O-antigen biosynthesis gene cluster in other B. oklahomensis strains (C6786, C7532, and C7533; data not shown). This may represent a lateral gene transfer event into EO147 and is deserving of additional study. Furthermore, regions within the two clusters had different levels of sequence conservation. Genes located at the ends of these two clusters (e.g., wbiGHI, and rmlBAC; Figure 1) had higher sequence similarity than most of the genes in the core of the clusters. Indeed, many of the cluster cores contain distinct gene composition. The conserved genes include those important for oligosaccharide synthesis and O-antigen biosynthesis [4].

LPS genotype frequencies were analyzed across a large strain collection using PCR-based assays. Multiplex-SYBR-Green PCR assays were designed to target a specific gene unique for each genotype. Gene wbiE (BPSL2676) of B. pseudomallei strain K96243 and gene BUC_3396 of strain 576 were used to represent the presence of LPS genotypes A and B, respectively (Figures 1&2). A total of 999 B. pseudomallei strains from different geographic locations and epidemiological origins (e.g., clinical, animal, and environmental strains) were tested for their LPS genotypes. We noted that 23 B. pseudomallei strains were collected from one melioidosis patient. We found that LPS genotype A was the most common genotype in both Australian and Southeast Asian strain populations (Figure 2). LPS genotype B was relatively rare in Southeast Asian strains (~2.3%), but was found in 13.8% of Australian strains. Five strains from Australia and two strains from Papua New Guinea were non-typeable using these two PCR gene markers. Three of these strains, MSHR840, MSHR1950, and MSHR139 were further analyzed for O-antigen biosynthesis gene identification using whole genome sequencing. The O-antigen biosynthesis gene clusters from these strains were identified and annotated (GenBank accession nos. GU574442, HM852062, HM852063). Comparative genomics demonstrated that many genes in this new cluster were similar to those of the LPS genotype B genes of B. pseudomallei 576 and were distinct from the K96243 LPS genotype A genes. Hence, these newly identified O-antigen biosynthesis gene clusters represent a variant of the LPS genotype B and, consequentially, were designated as LPS genotype B2 (Table 1). Figure 1 shows the genomic comparison of these three different O-antigen biosynthesis gene clusters: A, B, and B2 (from B. pseudomallei strains K96243, 576, and MSHR840, respectively). We note that %G+C content of the core of these 3 different clusters is relatively low (~59–60%) compared to the conserved parts of the O-antigen biosynthesis operon (~68%). This supports the hypothesis that these genomic differences are due to genetic recombination e.g., horizontal gene transfer, which is common in B. pseudomallei [15], [16]. Comparative genomics of these three different clusters using homologous-based alignment are summarized in Table S1. Again, we note that genes wbiGHI, and rmlBAC are conserved among these three different clusters. Furthermore, gene BURP840_LPSb16 from strain MSHR840 was selected for use as a PCR marker to represent the LPS genotype B2. PCR genotype analysis (Figure 2) revealed that all seven of the previously non-typeable strains were positive for the LPS genotype B2. The LPS B2 genotype was found only in strains from Australia and Papua New Guinea. It is important to note that there is no known clonal relationship among these seven strains. The LPS B2 genotype genes were also found in a B. thailandensis-like spp. strain MSMB121, which was isolated in Australia (unpublished data). Complete LPS genotypic data are reported in Table S2.

A novel LPS electrophoretic pattern - a type B variant

LPS genotyping results were further examined by direct comparison to LPS electrophoretic phenotypes [10]. Due to the difficulty of international Select Agent transfer and BSL3 handling, we phenotyped only ~ 24% of the isolates that were genotyped. We note that this is a limitation of our study. That said, all examined LPS A or B phenotypes were perfectly matched with their LPS A or B genotypes. In addition, 22 strains producing the rough LPS phenotype were all identified as LPS genotype A (Table S2). The genetic basis of the rough phenotype and its derivation from the A phenotype is known for only 16 of these strains (see below). SDS-PAGE revealed that LPS genotype B2 strains produced a distinct ladder pattern, though they were all detectable with type B sera using immunoblot hybridization. The B2 phenotype had a wider range of molecular weights (40–120 kDa) than the LPS types A and B. In total, three LPS banding patterns plus the rough LPS type (no ladder) can be detected (Figure 3).

Figure 3
Diversity of B. pseudomallei LPS banding patterns and their serological specificity.

Natural mutations in O-antigen genes and changes in bacterial phenotypes

A frame-shift mutation observed in the O-antigen biosynthesis wbiI gene of B. pseudomallei strain MSHR1655 was correlated with its rough phenotype. This is one of nearly 100 strains that were isolated over 8 years from a patient with severe bronchiectasis associated with melioidosis. The mutation was an extra guanine inserted after nucleotide position 815 of the wbiI gene (Figure 4). The wbiI gene encodes an oligosaccharide epimerase/dehydratase and is conserved in all O-antigen biosynthesis gene clusters of B. pseudomallei. A mutation in this gene probably impacts on the synthesis of the O-antigen in this bacterial strain. There were 23 serial B. pseudomallei isolates observed from the chronically infected patient and the wbiI gene sequences were determined in all of them to detect frame shift mutations. The frame-shift mutation occurred in 16 isolates, all of which were collected on or after day 550 of the infection. The wild type sequence was present in the other seven isolates from earlier in the infection (Figure 4). Moreover, phenotypic characterization revealed that LPS samples extracted from the 16 wbiI mutated strains did not have the O-antigen ladder pattern (i.e the rough phenotype) based upon SDS-PAGE and silver straining (Figure 5A). Thus, it seems likely the frame-shift mutation in the wbiI gene blocks synthesis of the O-antigen. A recent study has reported that oacA gene, known to be involved in the acetylation at the O-4 position of the L-6dTalp residues of B. thailandensis O-antigen [14], is mutated in B. pseudomallei MSHR1655. Since MSHR1655 was isolated from the same patient above, we then sequenced the oacA gene in all of these clonal strains. We found that the oacA mutation occurred in the same 16 strains that had the wbiI mutation (Figure 4C). Additional study of the oacA gene in other whole genome sequenced strains determined that B. pseudomallei 112 and B. thailandensis TXDOH also had point mutation in their oacA genes (Table 1; Figure S1). To determine if the oacA gene plays only a single role in the side group modification of the L-6dTalp residues, or a dual role in combination with the synthesis of the O-antigen, both strains were tested for O-antigen production and immunogenic specificity. We found that B. pseudomallei 112 and B. thailandensis TXDOH expressed O-antigen type A ladder pattern and their O-antigen bands were strongly positive with the B. mallei LPS-specific mAb 3D11 (Figure 6) that recognized the lack of 4-O acetylation of the L-6dTalp residues [14]. This suggests the oacA gene in B. pseudomallei and B. thailandensis has a role in the acetylation at the O-4 position of the O-antigen L-6dTalp residues but is not involved in the synthesis of the O-antigen. Thus, we determined that the rough LPS phenotype observed in the 16 clonal chronic lung strains was due to the mutation of their wbiI gene, but not from the effect of the oacA mutation. In this study, we also identified six other independent rough LPS strains, but mutations did not occur in their wbiI or oacA genes. Searching for mutations in other genes of these strains warrants a follow up study to understand alternate mechanisms that generate the rough phenotype.

Figure 4
Point mutations found in wbiI and oacA genes in clonal B. pseudomallei strains.
Figure 5
Differential LPS phenotypes and serum susceptibility of the chronic lung strains.
Figure 6
Phenotypic effects of the oacA mutation in B. pseudomallei 112 and B. thailandensis TXDOH revealed by immunoblot analysis.

Because LPS is essential for outer membrane integrity and serum resistance, four B. pseudomallei strains from this chronic lung patient were further tested in serum bactericidal assays. Two of the wbiI mutant strains that expressed the rough LPS phenotype (MSHR1655 and MSHR3042) were unable to grow in the presence of 30% normal human serum (NHS). In contrast, two early infection isolates from the same patient expressing the typical LPS A phenotype (MSHR1043 and MSHR1048) were able to resist the inhibitory human serum effect and grow (Figure 5B). Furthermore, we also confirmed that the LPS genotype B2 strains were killed in growth media containing 30% NHS, whereas the LPS genotype B strains were resistant (Figure S2). We believe that this finding of serum susceptibility in LPS genotype B2 is important and deserves further investigation.

Discussion

Two major (A, B) and one minor (B2) LPS genotypes exist unequally in B. pseudomallei populations

Despite the fact that genes responsible for the O-antigen biosynthesis in B. pseudomallei 1026b were identified many years ago [4], diversity of these genes across multiple B. pseudomallei strains has not been well studied until now. Advances in genome sequencing and comparative genomics have provided insights into the complexity and diversity of B. pseudomallei genomes. B. pseudomallei genomic studies can now strive for correlations between genomic diversity and differential phenotypes; perhaps the clinical outcomes of individual strains of B. pseudomallei may be predicted using basic genomic analysis. In our current study, we were able to establish a correlation between differential LPS phenotypes and diversity of O-antigen biosynthesis genes or known as LPS genotypes. Three different major LPS genotypes have been identified so far. LPS genotype A was designated to the strains that contained the O-antigen biosynthesis genes that were identical or very similar to those found in a reference strain 1026b [4], whereas the LPS genotype B category is represented by the atypical LPS strain 576. Finally, LPS B2 genotype was identified as a variant of the LPS genotype B because many of its O-antigen biosynthesis genes were similar to those of LPS genotype B, and both groups were serotype B positive. LPS genotype A was the most common genotype in both geographic locations: Southeast Asia and Australia where it accounted for 97.7% and 85.3% of the populations, respectively. Interestingly, the frequency of LPS genotype B was relatively high (approx. 13.8%) in Australian strains, whereas they accounted for only 2.3% of the strains from Southeast Asia. LPS genotype B2 was found in only 7 strains, 5 of which were from Australia, and the other 2 strains were from Papua New Guinea. In addition, LPS genotype B2 was also found in a member of B. thailandensis-like species which was recently discovered in Australia [22]. This would suggest that the LPS genotype B2 genes in B. pseudomallei may be acquired by horizontal gene transfer from a common soil bacterial species in Australia, or vice versa. Comparative genomics and phenotypic characterization of this LPS genotype B2 in B. pseudomallei and its near-relative species warrants further investigation.

Because the LPS genotypes B and B2 were frequently found in Australia but not in Southeast Asia, it is possible that this finding may be due to different therapies used for clinical cases in these 2 endemic locations. We have investigated this and found that the majority of these isolates were obtained before any exposure to antibiotics or treatment therapy. In addition, some of the LPS genotype B strains were collected from soil in Australia, and 2 strains of the LPS genotype B2 were found in animal cases. This confirms that the occurrence of LPS types B and B2 in Australia is not associated with the exposure to antibiotics or treatment therapy. Although, we phenotyped only 24% of the isolates that were genotyped, most tested strains were perfectly matched between their genotypes and phenotypes, except those 16 rough LPS genotype A strains from a single chronic case that had mutations in their wbiI genes (Figure 4). In this current study, we were unable to identify the genetic basis or mutations in 6 independent LPS genotype A strains that did not produce the O-antigen (Table S2).

Because the typical LPS was also found in B. thailandensis, the use of anti-LPS antibody based latex agglutination for the identification of B. pseudomallei in environmental specimens was not successful in an early study [23]. B. thailandensis LPS has also been shown to cross-react with rabbit and mouse sera obtained from inoculation with B. pseudomallei or B. mallei suggesting that LPS molecules from B. thailandensis, a non-pathogenic bacterium, may be useful in ongoing efforts to develop novel vaccines and/or diagnostic reagents [24]. This has brought to our attention whether low-grade B. thailandensis infections might naturally provide protection against melioidosis. Although the O-antigen biosynthesis genes in B. pseudomallei and B. thailandensis are similar, a recent study by a Singaporean group has revealed that lipid A components of the LPS from both B. pseudomallei and B. thailandensis must be different; the murine and human macrophages produced lower levels of tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-10 in response to B. pseudomallei LPS than in response to B. thailandensis LPS in vitro [25]. In our current study, the typical LPS was also found in B. oklahomensis strain EO147, formerly known as an American B. pseudomallei strain [26], suggesting that the typical LPS is widely spread in multiple Burkholderia species. This group includes highly pathogenic species such as B. pseudomallei and B. mallei, but also non-pathogenic species: B. thailandensis, B. thailandensis-like species, and B. oklahomensis. The evolution of LPS diversity across these closely related species is likely a function of differential selection and horizontal transfer of genetic elements. This diversity could play a role in frequency and distribution of disease in humans. However, without understanding molecular structures of these O-antigen types, it is difficult to access the phenotypic effects of this genetic diversity. Structural analysis of the O-antigen types B and B2 deserves further investigations. In addition, we have found that the LPS genotype B2 strains were sensitive to 30% NHS, whereas the LPS type B strains were resistant (Figure S2). This finding demonstrates a level of phenotypic differences between these two serologically related groups. We believe that the consequences for case treatment associated with these differential serum susceptibilities also warrant further investigations.

The rough LPS phenotype – Adaptation to survival and persistence in a host?

A previous study has shown that the two less common LPS phenotypes (smooth type B and rough type) were more prevalent in clinical than environmental isolates and more prevalent in Australian isolates than Thai isolates [10]. In our current study, LPS genotype B was found in both clinical and environmental strains from Australia, whereas the rough LPS was still found only in clinical strains. Based on our description of the molecular basis for LPS phenotypes, it is unlikely that B. pseudomallei will readily switch its LPS phenotype from A to B, or vice versa, as has been suggested previously [10]. The gene compositions of LPS genotypes A and B are very different and a simple switching mechanism is difficult to envision. In addition, we have found that at least some rough LPS strains have mutations in their O-antigen biosynthesis genes. These include 16 clonally related isolates from a single chronic lung infected patient (Table S2). All of these strains were identified as LPS genotype A with mutations in their O-antigen biosynthesis genes. Using Tn5-OT182 mutagenesis, DeShazer and colleagues identified at least seven genes in the O-antigen biosynthesis operon of B. pseudomallei 1026b that were responsible for O-antigen biosynthesis and serum resistance; these included rmlB, rmlD, wbiA, wbiC, wbiE, wbiG, and wbiI [4]. In our current study, we found point mutations in wbiI and oacA genes of B. pseudomallei isolates that were collected from a chronic lung patient (Figure 4). We hypothesize that the frame-shift mutation in the wbiI genes blocks O-antigen biosynthesis in all mutant strains, but not from the effect of the oacA mutation. This is because we observed the oacA mutations in B. pseudomallei 112 and B. thailandensis TXDOH that had normal O-antigen biosynthesis gene cluster (Table 1 and Figure S1). Our study has demonstrated that these two oacA mutant strains expressed O-antigens identical to those found in B. mallei due to lack of the 4-O acetylation of the L-6dTalp residues of the O-antigen. The lack of the 4-O acetylation of the L-6dTalp residues has recently been described in the oacA knock-out mutant B. thailandensis ZT0715 and a wild-type B. mallei ATCC23344 [14].

We have demonstrated that these wbiI mutant strains produced rough LPS and were sensitive to normal human serum suggesting that the wbiI gene encoding for epimerase, or dehydratase, was essential for the biosynthesis of B. pseudomallei O-antigen. Although loss of the O-antigen might compromise serum survival it might also be adaptive in particular niches. B. pseudomallei survival or persistence in the host might be enhanced without the surface presentation of the O-antigenic moiety of the LPS, as it would not be recognized by host immune systems and would, therefore, avoid being killed by antibodies. The O-antigenic polysaccharide of B. pseudomallei modulates the host cell response, which in turn controls the intracellular fate of B. pseudomallei inside macrophage. This was concluded from the observation that the O-antigen mutant B. pseudomallei strain SRM117 was more susceptible to macrophage killing during the early phase of infection than the parental wild-type strain 1026b [27]. This was also confirmed by the same group when they demonstrated the importance of intracellular killing by the human polymorphonuclear cells (PMNs), macrophages (Mϕs), and susceptibility to killing by 30% normal human serum [28].

LPS and CPS (capsular polysaccharide) have been used as subunits in immunizing BALB/c mice against B. pseudomallei infection [2]. Mice vaccinated with LPS developed predominantly IgM and IgG3 responses, whereas the mice vaccinated with the CPS developed a predominantly IgG2b response. Furthermore, immunization with the LPS provided an optimal protective response, and the immunized mice challenged by the aerosol route showed a small increase in the mean time to death compared with the unvaccinated controls [2]. Previously, it was shown that B. pseudomallei LPS from strain 1026b signaled through Toll-like receptor (TLR) 2 and not through TLR4 [29]. This was observed in the TLR2 knock-out mutant mice that displayed a markedly improved host defense, but it was not observed in TLR4 knock-out mice [29]. In contrast, a study in HEK293 cells demonstrated that heat-killed B. pseudomallei strains K96243 or BP-1 activated TLR2 and TLR4, and in the presence of MD-2, LPS and lipid A from BP-1 are TLR4 ligands [30]. We note that B. pseudomallei 1026b and K96243 expressed the typical O-antigen type A, but the O-antigen type of BP-1 was not reported in that study. Although there was no report of association between the LPS types and disease severity (e.g., fatal versus non-fatal, and septicemia versus localized), clinical manifestations (neurologic versus non-neurologic), or underlying risk factors (diabetic versus non-diabetic) observed in a previous study [10], full phenotypic characterization including virulence in animal models, innate immune response, etc of these different LPS types warrants further investigations given the LPS diversity that we have described.

Supporting Information

Figure S1

Point mutations found in gene BPSL1936 (oacA homolog) of B. pseudomallei MSHR1655 and 112, and B. thailandensis TXDOH. These point mutations (panel A): in strain MSHR1655, the mutation was associated with 2 extra bases, “TC”, inserted right after nucleotide no. 298 of this gene; in strain 112, it was associated with a deletion of one base, “T”, at nucleotide no. 112; and in B. thailandensis TXDOH, it was associated with the 5′ truncation mutation. Amino acid sequence analysis (panel B) has demonstrated that the point mutations in MSHR1655 and 112 potentially caused frame-shift mutations in their BPSL1936 genes, and then split the gene into 2 separated open reading frames (ORFs). Two known amino acid motifs, VXXFFXXSG and WXLXXEXXXY, were present in both ORFs of MSHR1655, whereas only the latter motif was present in strain 112. We noted that both amino acid motifs were absent in B. thailandensis TXDOH.

(PPT)

Figure S2

O-antigen types and differential serum susceptibility. O-antigen type A and B strains including B. pseudomallei 1026b, NCTC13178, and NCTC13179, MSHR367b, MSHR98, respectively, were resistant to 30% normal human serum (NHS); whereas the O-antigen type B2 strains : B. pseudomallei MSHR840, MSHR454, and MSHR1950, and B. thailandensis-like sp. strain MSMB121 were sensitive to the 30% NHS. A rough O-antigen type strain MSHR3042, a member of the chronic lung strains (see text), was also sensitive. We noted that B. thailandensis E264 was able to survive, but unable to multiple in the presence of 30% NHS. E. coli HB101 was used as a control serum sensitive strain.

(PPT)

Table S1

Comparison of LPS genotype A, B, and B2 gene clusters.

(DOC)

Table S2

List of bacterial strains used in this study and their LPS genotyping PCR results.

(XLS)

Acknowledgments

We thank Judy Lee, Stephanie Grasso, Dawn Birdsell, Amanda Pettus, Eleanor Woolveridge, and Yuwana Podin for their technical assistance.

Footnotes

The authors have declared that no competing interests exist.

This project was funded by National Institutes of Health-National Institute of Allergy and Infectious Diseases Grant U54 AI-065359 and U01 AI-075568 to PK and United States Department of Homeland Security award no. HSHQDC-10-C-00135 to AT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Caroff M, Karibian D. Structure of bacterial lipopolysaccharides. Carbohyd Res. 2003;338:2431–2447. [PubMed]
2. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, et al. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. Journal of Medical Microbiology. 2004;53:1177–1182. [PubMed]
3. Sarkar-Tyson M, Thwaite JE, Harding SV, Smither SJ, Oyston PCF, et al. Polysaccharides and virulence of Burkholderia pseudomallei. Journal of Medical Microbiology. 2007;56:1005–1010. [PubMed]
4. DeShazer D, Brett PJ, Woods DE. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Molecular Microbiology. 1998;30:1081–1100. [PubMed]
5. Leon CG, Tory R, Jia J, Sivak O, Wasan KM. Discovery and development of Toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharmaceutical Research. 2008;25:1751–1761. [PMC free article] [PubMed]
6. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, et al. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg. 2010;82:1113–1117. [PMC free article] [PubMed]
7. Charuchaimontri C, Suputtamongkol Y, Nilakul C, Chaowagul W, Chetchotisakd P, et al. Antilipopolysaccharide II: An antibody protective against fatal melioidosis. Clinical Infectious Diseases. 1999;29:813–818. [PubMed]
8. Ho M, Schollaardt T, Smith MD, Perry MB, Brett PJ, et al. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infection and Immunity. 1997;65:3648–3653. [PMC free article] [PubMed]
9. Arjcharoen S, Wikraiphat C, Pudla M, Limposuwan K, Woods DE, et al. Fate of a Burkholderia pseudomallei lipopolysaccharide mutant in the mouse macrophage cell line RAW 264.7: Possible role for the O-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival. Infection and Immunity. 2007;75:4298–4304. [PMC free article] [PubMed]
10. Anuntagool N, Wuthiekanun V, White NJ, Currie BJ, Sermswan RW, et al. Short report: Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. American Journal of Tropical Medicine and Hygiene. 2006;74:348–352. [PubMed]
11. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infection and Immunity. 1995;63:3348–3352. [PMC free article] [PubMed]
12. Ngugi SA, Ventura VV, Qazi O, Harding SV, Kitto GB, et al. Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine. 2010;28:7551–7555. [PubMed]
13. Burtnick MN, Deshazer D, Woods DE. Molecular and physical characterization of Burkholderia mallei O antigens. J Bacteriol. 2002;184:849–852. [PMC free article] [PubMed]
14. Brett PJ, Burtnick MN, Heiss C, Azadi P, DeShazer D, et al. Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-like O polysaccharides. Infection and Immunity. 2011;79:961–969. [PMC free article] [PubMed]
15. Tuanyok A, Leadem BR, Auerbach RK, Beckstrom-Sternberg SM, Beckstrom-Sternberg JS, et al. Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics. 2008;9:566. [PMC free article] [PubMed]
16. Tuanyok A, Auerbach RK, Brettin TS, Bruce DC, Munk AC, et al. A horizontal gene transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol. 2007;189:9044–9049. [PMC free article] [PubMed]
17. U' Ren JM, Schupp JM, Pearson T, Hornstra H, Clark CL, et al. Large tanden repeat regions within Burkholderia pseudomallei genome and their application for high resolution genotyping. BMC Microbiology. 2007;7:23. [PMC free article] [PubMed]
18. Chantratita N, Wuthiekanun V, Boonbumrung K, Tiyawisutsri R, Vesaratchavest M, et al. Biological relevance of colony morphology and phenotypic switching by Burkholderia pseudomallei. J Bacteriol. 2007;189:807–817. [PMC free article] [PubMed]
19. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18:383–416. [PMC free article] [PubMed]
20. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis. 2010;4:e900. [PMC free article] [PubMed]
21. Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, et al. ACT: the Artemis Comparison Tool. Bioinformatics. 2005;21:3422–3423. [PubMed]
22. Gee JE, Glass MB, Novak RT, Gal D, Mayo MJ, et al. Recovery of a Burkholderia thailandensis-like isolate from an Australian water source. BMC Microbiol. 2008;8:54. [PMC free article] [PubMed]
23. Wuthiekanun V, Anuntagool N, White NJ, Sirisinha S. Short report: A rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis. Am J Trop Med Hyg. 2002;66:759–761. [PubMed]
24. Qazi O, Prior JL, Judy BM, Whitlock GC, Kitto GB, et al. Sero-characterization of lipopolysaccharide from Burkholderia thailandensis. Trans R Soc Trop Med Hyg. 2008;102:S58–60. [PMC free article] [PubMed]
25. Novem V, Shui GH, Wang DL, Bendt AK, Sim SH, et al. Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clinical and Vaccine Immunology. 2009;16:1420–1428. [PMC free article] [PubMed]
26. Nussbaum JJ, Hull DS, Carter MJ. Pseudomonas pseudomallei in an anopthalmic orbit. Arch Opthalmol. 1980;98:1224–1225. [PubMed]
27. Arjcharoen S, Wikraiphat C, Pudla M, Limposuwan K, Woods DE, et al. Fate of a Burkholderia pseudomallei mouse macrophage cell line lipopolysaccharide mutant in the RAW 264.7: Possible role for the o-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival. Infection and Immunity. 2007;75:4298–4304. [PMC free article] [PubMed]
28. Wikraiphat C, Charoensap J, Utaisincharoen P, Wongratanacheewin S, Taweechaisupapong S, et al. Comparative in vivo and in vitro analyses of putative virulence factors of Burkholderia pseudomallei using lipopolysaccharide, capsule and flagellin mutants. FEMS Immunol Med Microbiol. 2009;56:253–259. [PubMed]
29. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, et al. Toll-like receptor 2 impairs host defense in Gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Medicine. 2007;4:e248. [PMC free article] [PubMed]
30. West TE, Ernst RK, Jansson-Hutson MJ, Skerrett SJ. Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunology 9 2008 [PMC free article] [PubMed]

Articles from PLoS Neglected Tropical Diseases are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...